|
IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
DK0759299T3
(da)
*
|
1995-08-16 |
2000-08-07 |
Lilly Co Eli |
Potensering af serotoninrespons
|
|
IN182588B
(OSRAM)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
|
IN186677B
(OSRAM)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
|
EP1276478A2
(en)
|
2000-04-24 |
2003-01-22 |
ARYx Therapeutics |
(2-aminoethyl) oxime derivatives for the treatment of depression
|
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
MXPA04003358A
(es)
*
|
2001-10-12 |
2004-07-08 |
Serenix Pharmaceuticals Llc |
Antagonistas de vasopresina v1a de ?-lactamilo.
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
|
AU2004271800A1
(en)
|
2003-09-12 |
2005-03-24 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
|
KR20070004036A
(ko)
*
|
2004-04-29 |
2007-01-05 |
키스톤 리테이닝 월 시스템스, 아이엔씨 |
벽, 옹벽 및 그 외 유사한 것을 위한 베니어
|
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
AU2006227199A1
(en)
|
2005-03-22 |
2006-09-28 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
CN101203218A
(zh)
*
|
2005-04-22 |
2008-06-18 |
惠氏公司 |
苯并呋喃基链烷胺衍生物和其作为5-ht2c激动剂的用途
|
|
AU2006239897A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
|
CN101203216A
(zh)
*
|
2005-04-22 |
2008-06-18 |
惠氏公司 |
二氢苯并呋喃衍生物及其用途
|
|
CN101175740A
(zh)
|
2005-04-22 |
2008-05-07 |
惠氏公司 |
二氢苯并呋喃衍生物和其用途
|
|
SG163588A1
(en)
*
|
2005-07-08 |
2010-08-30 |
Braincells Inc |
Methods for identifying agents and conditions that modulate neurogenesis
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
CA2615813C
(en)
*
|
2005-07-19 |
2015-12-15 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
|
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
AU2007231011A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
|
CA2651813A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
CA2662491A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
CA2675132A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
ES2735411T3
(es)
|
2009-10-23 |
2019-12-18 |
Janssen Pharmaceutica Nv |
Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
|
|
WO2011071995A2
(en)
|
2009-12-08 |
2011-06-16 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
|
CN107007596A
(zh)
|
2010-07-01 |
2017-08-04 |
阿泽凡药物公司 |
用于治疗创伤后应激障碍的方法
|
|
AU2012227936A1
(en)
|
2011-03-17 |
2013-10-17 |
Lupin Limited |
Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
|
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
|
EP2981518B1
(en)
|
2013-04-03 |
2021-03-03 |
ZCL Chemicals Ltd. |
"an improved process for the preparation of fluvoxamine maleate"
|
|
CN106456578B
(zh)
|
2014-02-07 |
2020-02-18 |
匈牙利科学院大学及其他机构附属研究所 |
Sigma-1受体激动剂化合物的用途
|
|
NZ724718A
(en)
|
2014-03-28 |
2023-04-28 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
|
CA2960253A1
(en)
|
2016-03-10 |
2017-09-10 |
Janssen Pharmaceutica Nv |
Methods of treating depression using orexin-2 receptor antagonists
|
|
WO2018096376A1
(en)
|
2016-11-24 |
2018-05-31 |
Mta Támogatott Kutatócsoportok Irodája |
Compositions for organ preservation
|
|
WO2019055913A1
(en)
|
2017-09-15 |
2019-03-21 |
Azevan Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
|
|
MX2022000709A
(es)
|
2019-07-19 |
2022-05-19 |
Bioxcel Therapeutics Inc |
Regimenes de tratamiento con dexmedetomidina no sedante.
|
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|